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Neurodegenerati on with brain iron accumulation (NBIA) describes a heterogeneous family of diseases characterized by high brain iron, particularly in the basal ganglia. The most common manifestation of NBIA in childhood is the disease pantothenate kinaseYassociated neurodegeneration (PKAN). PKAN is a type of autosomal recessive neuroaxonal dystrophy caused by mutations in the PANK2 gene; the PANK2 enzyme is normally responsible for the first step in coenzyme A biosynthesis. 1 Classic PKAN is characterized by early onset (typically younger than 6 yrs) with rapid disease progression, whereas atypical PKAN has an average age of onset of 14 yrs and progresses more slowly. Although there is currently no established therapy for PKAN, various drugs are used to alleviate or lessen its symptoms. Baclofen, a gammaaminobutyric acid receptor agonist, is one of the Bmainstay drugs[ used to treat dystonia in patients with PKAN. 4 It is often administered via an intrathecal baclofen (ITB) pump and has been recommended as a safe and effective treatment of dystonia. 5 ITB for the treatment of dystonia was first reported 6 in 1991. It has been suggested that ITB for the treatment of dystonia is more effective in patients who also have spasticity or pain, 7 both of which have been observed in PKAN. In a study of seven patients with PKAN treated with ITB, Albright et al. 8 found that, although parents reported improvements in ease of care and severity of dystonia, there was no statistically significant difference in dystonia scores. Woon et al. 5 found that treatment with ITB in patients with PKAN improved vocalization, swallowing, drooling, fine motor skills, and ease of care. More recently, intraventricular baclofen delivery has been used to treat PKAN, with favorable outcomes. However, further investigation into dosage and efficacy of this technique is needed. 9 Deferiprone (1,2-dimethyl-3-hydroxypyrid-4one or L1) is an iron chelator that was first used in patients with thalassemia receiving blood transfusions. It has been shown to cross the blood-brain barrier and to remove intracellular iron as well as to act as a reverse siderophore by way of iron redistribution. 10Y13 Deferiprone as a treatment of NBIA was first reported in 2008 in a 61-yr-old woman, with treatment resulting in reduced brain iron deposition, improved gait, and decreased incidence of choreic dyskinesias. 14 Subsequent pilot trials investigating deferiprone for the treatment of PKAN have found that the drug is safe and tolerable as well as effective in reducing brain iron accumulation as measured by magnetic resonance imaging. However, the standard dose of deferiprone used for hemocyderosis may be associated with increased neurotoxicity in patients with PKAN. The link between the clinical and radiological findings, however, is unclear because only mild to moderate motor improvement was noted in some patients in one study (dosage of 30 mg/kg per day) 15 and no clinical improvement was noted in the other study (dosage of 25 mg/kg per day). 16 Studies in patients with thalassemia have shown the side effects of the drug to include agranulocytosis, musculoskeletal pain, and zinc deficiency, so monitoring of blood count, iron balance, and liver and renal function has been used in patients treated with deferiprone. Both pilot trials emphasized the need for an international, placebo-controlled, long-term study to investigate the clinical efficacy of iron chelation treatment of PKAN. 15, 16 This case report highlights the potency of combining ITB and oral deferiprone in a patient with classic PKAN. Although treatment with deferiprone alone was not attempted, this combination therapy seems to be more efficacious than treatment with only ITB. Born without complications and full term, the patient was treated early in life for suspected attention-deficit/hyperactivity disorder and bipolar disorder. At the age of 5 yrs, he was diagnosed with retinitis pigmentosa and subsequently declared legally blind. However, because he was, at the time, fully functional, further investigation into the cause of his blindness and behavioral disorders was not pursued.
At the age of 10 yrs (2007), a magnetic resonance imaging scan of the patient's brain confirmed the presence of iron deposition in the basal ganglia (see Fig. 1 ). Because his symptoms began when he was younger than 6 yrs, the patient was diagnosed with classic, rather than atypical, PKAN. The disease progressed so severely that within 18 mos, he went from a fully functional young boy to a 12-yr-old with severe disability. By the age of 11 yrs (2008), he was unable to walk; at the height of his dystonia (age of 12 yrs), he tolerated only a prone position and was constantly in an opisthotonic posture supported by pillows, with the upper extremities, the trunk, and the lower extremities in severe hyperextension. He was unable to sit in a wheelchair and was therefore transported in a wagon. At the age of 11 yrs, bilateral deep brain stimulators (DBSs) were placed in an attempt to manage his dystonia on the basis of positive published results on the use of DBS for dystonia. 17, 18 The implanted pulse generator was placed in the patient's abdomen, rather than in the more common infraclavicular location, because of his small size and poor nutritional status to improve tissue coverage over that available in the chest. However, this treatment seemed ineffective and was subsequently disconnected 8 mos after implantation.
During disconnection and battery removal of the DBSs, an ITB pump was implanted, with the catheter tip placed at C2 (see Fig. 2 ). This decision was made on the basis of a very good response to an ITB trial of 100 Kg. During the 3-hr trial period, improved Ashworth Scale scores (see Table 1 ) and clearer speech, the regained ability to chew without gagging or choking, decreased opisthotonic arching, the ability to open both hands upon command, and knee extension past 90 degrees were noted. After ITB pump implantation, the patient received 1050 Kg of baclofen per day as well as oral baclofen (10 mg) and diazepam (4 mg) as needed for stiffness. Oral baclofen was given as a supplement because it was thought that oral medication might potentiate the effects of ITB. It was noted that baclofen was helpful in managing his dystonia and Feeding was another complex issue in this patient. In 2009, he was seen by gastroenterology about feeding and weight loss concerns. Although, at this time, he was still able to take food orally, doing so was complicated by significant coughing and swallowing difficulties. He was placed on bolus nasogastric tube feeds with Nutren Junior and was consulted by surgery for the placement of a gastrostomy tube. However, because of his consistent opisthotonic posturing and the presence of instruments within his abdomen, the surgeon felt that a gastrostomy tube would be mechanically difficult for him. His mother reported about a 20-lb weight gain after nasogastric tube placement but also complained that he would pull out the nasogastric tube at least once a week. He had two hospitalizations for aspiration pneumonia, which his mother felt were because of his repeated purposeful removal of the tube.
Although ITB seemed to cause significant improvements in this patient, his complex medical management encouraged the pursuit of other therapeutic drug options. In July 2009, the Food and Drug Administration granted Compassionate Use Investigational New Drug approval for the use of deferiprone in the patient. He was administered a low dose of oral deferiprone twice daily. On checkup, 1 mo later, he presented with a 14-lb weight gain and was again able to sit in his wheelchair. Because of this regained ability, he was again consulted for gastrostomy tube placement, which was performed in December 2010, mainly for the concern of aspiration. In a follow-up visit, slightly more than a year after treatment with deferiprone was started, remarkable improvement was noted, especially in the extent of his dystonia. Better head movements and the ability to lift his leg were also noted by the physician, and the patient's mother reported that, while at home, he was interactive, responded to conversation, and was able to answer yes or no by lifting his elbow. Range of motion measurements before and after treatment with deferiprone are reported in Table 2 .
Treatment with deferiprone was interrupted only for intercurrent infections. There seemed to be no other physical side effects of the drug such as neutropenia or joint swelling. The patient's liver function has been stable, with no changes in his metabolic panel. In screening for iron deficiency, decreases in ferritin and transferrin saturation were noted, and low-dose iron supplementation was started (2 mg/kg per day) on the basis of recommendation by the physician responsible for his deferiprone dosage and hematologic oversight. Because deferiprone has a tendency to chelate areas with high levels of iron, it also removes some circulating iron. Supplemental iron was therefore Treatment of Classic PKAN started to keep the blood levels of ferritin normal, subsequently keeping red blood cell levels normal; the previously observed low ferritin has since been normalized. There has been no hematologic manifestation of such iron deficiency because mean corpuscular volume, red blood cell distribution width, and hemoglobin levels actually improved (see Table 3 ). The patient is currently taking, among other medications, 40 mg of diazepam per day, 1035 Kg of ITB per day, 1000 mg of deferiprone per day, and 6.1 mg of ferrous sulfate per day. He remains stable, and further side effects of ITB or deferiprone have not been reported.
DISCUSSION
This 15 yr old diagnosed with classic PKAN progressed, upon treatment with ITB and oral deferiprone, from a boy in constant opisthotic posture who was carried in a wagon to being able to sit in a wheelchair. The patient was treated with a daily dosage of deferiprone just in between that used in recent pilot trials. 15, 16 However, his baclofen dose was higher than that given in previous studies on ITB as a treatment of dystonia. 5, 19 No adverse side effects of either drug were reported, aside from decreases in ferritin and transferrin saturation, which were not reflected in the hematologic measurements such as mean corpuscular volume, red blood cell distribution width, or hemoglobin level. He has now been treated with ITB and oral deferiprone for 3 yrs; his mother reports greater ease of care, is happy with the treatment outcome, and wishes to continue therapy with both drugs.
This case highlights the fact that although there is no approved treatment of PKAN, drugs such as baclofen and deferiprone may lead to marked improvements in quality-of-life, dystonia, and ease of care for these patients. Although deferiprone is only variably efficacious with regard to clinical improvements, 15, 16 some patients such as the one presented in this study may derive great benefit from taking the drug. ITB therapy has also been shown to decrease the extent of dystonia in patients with PKAN, as was observed in this patient. The authors recommend that patients with severe, progressive dystonia and classic PKAN be considered for dual treatment with ITB and deferiprone.
On the basis of this and two other cases of PKAN treated with deferiprone under an investigational new drug at Children's Hospital and Research Center Oakland, a large-scale, phase-three, placebocontrolled trial will be pursued. This international trial will begin enrolling patients with PKAN for treatment with deferiprone in the fall of 2012, with Children's Hospital and Research Center Oakland serving as the United States site involved in the study. This clinical trial is supported by both the Food and Drug Administration and a Framework 7 European Union grant, Treat Iron Related Childhood Onset Neurodegeneration. MCV indicates mean corpuscular volume; RDW, red blood cell distribution width.
